Vanguard Global Advisers’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.25M Buy
25,575
+6,011
+31% +$624K ﹤0.01% 1169
2026
Q2
$1.91M Buy
19,564
+1,829
+10% +$160K ﹤0.01% 1289
2026
Q1
$1.49M Buy
+17,735
New +$1.03M ﹤0.01% 1392

Other funds holding DNTH

Vanguard Global Advisers's DNTH Position: Q3 2026 in Review

Vanguard Global Advisers increased its Dianthus Therapeutics (DNTH) stake by 31% in Q3 2026, buying an estimated $624K and bringing the position to 25,575 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Vanguard Global Advisers first reported a position in DNTH in Q1 2026 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Vanguard Global Advisers held 25,575 shares of Dianthus Therapeutics worth $2.25M as of Q3 2026.
  • Vanguard Global Advisers bought 6,011 Dianthus Therapeutics shares in Q3 2026, an estimated $624K.
  • Dianthus Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1169 holding.
  • Vanguard Global Advisers first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 272 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.